Victorian poultry farmer recovering from 'devastating' bird flu outbreak
A Victorian farmer who had to kill more 500,000 chickens to control an outbreak of bird flu has detailed the financial and emotional cost of the "devastating" ordeal.
Phillip Szepe and his wife, Jane Szepe, own Kinross Farms near Euroa in the state's north, where bird flu was detected on four separate free-range egg farms.
The outbreak began in Febuary and was contained earlier this month.
Mr Szepe said the loss of his chickens and the massive clean-up operation took an emotional and financial toll on his family and business.
"It's been very emotional — our team were devastated and to see that loss of birds euthanased on such a scale is completely gut-wrenching and very traumatic," he said.
"We took all possible precautions in terms of managing the welfare and biosecurity of our birds at all times … but it's been pretty tumultuous.
Mr Szepe said the quarantine process was "like a scene out of CSI".
"People were in full biohazard suits, washing down areas, which was pretty intimidating, but that's what's necessary to managing the response and ensure we contained the virus to that area," he said.
When the business returns to full production by mid-September it will supply 1.2 million eggs per day to supermarkets.
"Retail shelves are now a lot fuller than what they have been, reflecting the recovery process with some of the farms affected by the prior outbreak just coming back to full production," Mr Szepe said.
Kinross Farms was in the process of being purchased by New South Wales-based egg producer Pace Farm at the time of the outbreak.
The sale is expected to be finalised within weeks.
"Pace Farms supported us getting back into production as soon as possible with replacement birds they had available and they'd had similar experiences in the past, so they knew what was involved and there's no one to blame for what eventuated," Mr Szepe said.
Multiple variants of avian influenza are present in Australia's wild bird population and can spread into commercial poultry farms directly from chickens being exposed to wildlife or from poor biosecurity practices such as dirty footwear.
Australia is the only continent that has not been hit with the H5N1 subtype of the disease, which is spreading among multiple animals internationally.
Mr Szepe is acutely aware of the threat the strain poses.
"All you need is wild ducks or waterfowl to frequent the ranging area and you've got the potential for transmission … we believe that's what happened, despite our best endeavours and leading edge technology," he said.
"We also have artificial intelligence lasers that detect ducks and then frighten them away with a high-resolution light.
"Any person who enters our farms has to go through a shower facility, leave street clothes outside and put on our uniforms and, if you have personal items such as a phone or glasses, they have to be UV sanitised."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
2 hours ago
- ABC News
Doctors at Westmead Hospital to hold vote of no confidence in health district chief executive, amid delayed cancer scans
Doctors at Sydney's Westmead Hospital are calling for their chief executive to stand down over allegations of patient safety concerns and delayed cancer diagnoses. In a letter sent to hospital staff, the Medical Staff Council said it plans to hold a vote of no confidence in Western Sydney Local Health District's chief executive, Graeme Loy, on Thursday evening. Senior doctors say for the past five years they have raised concerns about unacceptable clinic wait times for routine scans that can detect preventable cancers, with some patients waiting up to three years. "You will be aware that the [Medical Staff Council] has advocated for many years for improvement in patient care including excessive delays in clinic review, procedures and surgical admissions," deputy chair of the Westmead Medical Staff Council Jenny King wrote in the letter. "This has been a particular concern for those patients with a positive faecal occult blood screen. "The issue of failure to provide care for those patients at high-risk malignancy has long been documented," Dr King wrote. Western Sydney Local Health District, Health Minister Ryan Park and NSW Health have been contacted for comment. The revolt among staff came after the dismissal of Westmead's head of gastroenterology department, Jacob George, last week, who raised concerns with management about the lengthy wait times. One senior doctor at Westmead, who spoke on the condition of anonymity, believed Professor George's dismissal was retaliation for speaking out. "For many years we have been struggling to have our concerns listened to, and the executive has been aware," the doctor said. The ABC understands wait times have impacted cancer diagnosis screenings in several departments including cardio, renal, dermatology and gastroenterology. The senior doctor said the delays could mean hundreds of patients who have cancer are in the dark about their disease, or receive late diagnoses. "It's a major risk and it's something we shouldn't be letting people down on," the doctor said. "If you have a possible cancer, we like to get a colonoscopy done within 30 days, but patients are waiting months, and the risk is the cancer has disseminated." Kathryn Austin, Australian Medical Association NSW president, said the issues were symptomatic of a lack of investment in staffing in public hospitals. "There has not been the investment in workforce that we need and the workforce is who deliver the care to patients," she said. "It's a sad state of affairs that it's come to this point and the clinical concerns haven't been addressed." A vote of no confidence has no binding power and does not mean Mr Loy will be dismissed from this role if passed. But the senior doctor said the significance of an unanimous vote would be hard to ignore. "If we don't win, the whole of public health is threatened," the senior doctor said.
News.com.au
4 hours ago
- News.com.au
Health Check: Paradigm makes scenic acquisitive detour, but it's no strategic shift
Paradigm Biopharmaceuticals will spend up to $16.5 million on an oral drug asset, but stays focused on its phase III knee trial Percheron enters headline $450 million cancer drug acquisition Neurizon goes from solid to liquid with its motor neurone disease drug candidate Paradigm Biopharmaceuticals (ASX:PAR) is taking the acquisitive scenic route in its quest to develop an effective knee osteoarthritis treatment, but says it remains focused on its phase III knee trial. In a heavily back-ended deal, Paradigm will pay as much as $16.5 million to purchase Proteobioactives Pty Ltd. This company owns an early-stage oral candidate for minor to mild osteoarthritis (OA), called Pentacoxib. The proposed drug combines pentosan polysulfate sodium (PPS) – Paradigm's core asset – with a COX-2 inhibitor (Coxib). The idea is to improve drug 'bioavailability': a shortcoming of many oral drugs. The deal expands Paradigm's remit into the OA-related pain market, such as hand OA, mild knee OA and the veterinary market (dogs and horses). Proof of concept data shows meaningful pain reduction in patients with hand and knee OA. 'Strategic alignment' Paradigm touts Pentacoxib as an alternative to existing nonsteroidal anti-inflammatory drugs (NSAIDs), which are 'not known to improve structures of the arthritic joint'. Paradigm dubs the purchase as a 'strategic alignment' with its core program, which is about developing its repurposed PPS (Zilosul) for moderate to severe knee OA. The acquired asset moves the company down the OA 'severity spectrum' and maintains Paradigm's focus on a non-opioid alternative. Proteobioactives was founded by Professor Peter Ghosh, who pioneered PPS research. The deal gives Paradigm exclusive global rights to develop and commercialise the PPS-Coxib combo for pain and inflammation. The acquisition enables 'potential expansion into earlier-stage disease segments where large unmet needs remain.' Now to the financial nitty gritty: The deal involves an upfront $500,000 in cash and a $1 million milestone payment on completion of a phase II trial. Paradigm pays a further $5 million on 'successful completion' of a phase III trial. A further $5 million is paid on US Food & Drug Administration approval. There's more! Another $5 million is due on the sale of an FDA registered product, 'as evidenced by the submission of a sales invoice, proof of delivery, or other relevant documentation". Keep your receipts guys! The deal is modest bet for Paradigm relative to its long-awaited phase III knee OA. The study in underway across up to 15 Australian and 50 US sites. Percheron finds a new purpose Having scoured for a new asset following the failure of its flagship clinical program, Percheron Therapeutics (ASX:PER) has settled on a Singapore-based cancer drug candidate. This is by way of an exclusive license agreement with Hummingbird Bioscience, for a monoclonal antibody therapy with potential applications in several cancers. Percheron hopes to start a clinical trial of the candidate, dubbed HMBD-002, next year. Percheron will pay Hummingbird an upfront US$ 3 million ($4.6 million), with contingent milestone payments of up to US$287 million ($443 million), plus royalties to boot. Naturally, the big bucks are later in the piece. Taking in the VISTA HMBD-002 targets a bodily agent called VISTA, as in 'v-domain immunoglobulin suppressor of T-cell activation'. But we knew that already. A novel target, 'VISTA potentially represents a new mechanism to treat a diverse range of tumours.' HMBD-002 has passed a phase I trial in the US, which showed the agent to be 'pharmacologically active" and generally safe and well-tolerated. 'After the challenges of recent months, we are once again a mid-clinical stage drug development business,' says Percheron CEO Dr James Garner. The 'challenges' refer to two board spills – both unsuccessful – after the company's Duchenne muscular dystrophy trial proved an unmitigated flop. Percheron shares this morning rebounded as much as 30%, or one-third of a cent. Neurizon eyes easier drug delivery While Paradigm goes from liquid to solid, Neurizon Therapeutics (ASX:NUZ) is moving the other way with its drug candidate to treat amyotrophic lateral sclerosis (ALS, a form of motor neurone disease). The liquid formulation of Neurizon's candidate NUZ-001 is designed to support patients with all stages of ALS, 'particularly those with swallowing difficulties such as bulbar onset'. The first manifestation of ALS, bulbar onset can lead to difficulties with speech (dysarthria), swallowing (dysphagia), and sometimes breathing. Neurizon will integrate the liquid form into its ongoing NUZ-001 program, starting with a human bioequivalence study in the first half of 2026. The company says the formulation resulted from direct feedback from patients and carers. 'As ALS progresses, patients face increasing challenges with day-to-day activities, including something as fundamental as swallowing,' Neurizon chief Dr Michael Thurn says. Rainforest foraging leads to cancer drug hope The private, eternal IPO candidate Qbiotics has reported 'highly encouraging' results from a phase II study of its cancer therapy sourced from the Daintree rainforest. The trial targets soft tissue sarcoma, a rare cancer that generally forms as a painless lump (tumour) in any one of the soft tissues in the body. Qbiotics' candidate, tigilanol tiglate activates a certain protein to stimulate the immune system and destroy tumours. In stage one of the trial, ten evaluable patients achieved an objective response rate of 80%, 'based on the best observed response". In other words, eight out of ten evaluable patients saw either complete ablation or partial ablation (more than 30% reduction in volume) of treated tumours. Also, 22 of the 27 injected tumours across all patients showed complete or partial ablation (14 showing complete ablation). None of the 14 completely ablated tumours recurred at 6 months, "indicating tigilanol tiglate may provide durable responses". 'Given soft tissue sarcoma is a challenging cancer to treat, achieving this level of clinical activity is highly encouraging," Qbiotics chief Stephen Doyle says. Now moving to expanded stage two, the trial is being carried out at New York's Memorial Sloan Kettering Cancer Center. Eureka! moment Qbiotics founder Dr Gordon and her forest ecologist husband Dr Paul Reddell stumbled on the therapeutic benefits of tigilanol tiglate while fossicking in rainforest in the Atherton Tablelands of Far North Queensland. They observed that animals spat out the seed of the blushwood tree, pointing to a nontoxic deterrent preventing the critters from eating and thus destroying the seed.
ABC News
6 hours ago
- ABC News
How to limit the spread of COVID, cold and flu at home in winter
Winter can be a contagious time of year for everything from COVID-19 to the common cold. Once someone in your household feels the first ominous tickle at the back of their throat, everyone else can feel doomed to follow. "It's always a challenge within households because we know households are the place where viruses like respiratory viruses spread really efficiently," says Catherine Bennett, Deakin University's chair of epidemiology. But there are ways to limit the risk of illnesses spreading from one family member or housemate to another, she says. Professor Bennett says if someone within your household becomes sick, it is possible you have already been exposed before they had any symptoms. However, if the sick person can isolate from the rest of household it's still worth it, she says. Ideally this would look like using a separate bedroom and bathroom to others. She says this degree of isolation is not possible or realistic for many households. Isolation can also look like someone sleeping on the couch to "reduce their risk of inhaling the virus" from their unwell partner overnight, she says. Medical director for government-funded online public health information service Healthdirect Darran Foo says if possible, the symptomatic person should remain isolated from the rest of the household until they no longer have active symptoms. For example, "no more ongoing fevers, no more coughing up lots of phlegm". If someone in the household is symptomatic, and isolating completely is not possible, Professor Bennett says a mask can help protect the rest of the household. "Wearing a mask if you're unwell can reduce your risk of passing it on to other people." Dr Foo also advises wearing a mask if it's possible and practical, particularly if you live in a smaller home like an apartment. Dr Foo recommends throwing used tissues away immediately and avoiding sharing cups, plates and cutlery in the household when someone is unwell, whether from a cold or COVID-19. "The biggest thing really is to maintain good hygiene, especially good hand hygiene," Dr Foo says. "Lots of hand washing and using sanitisers as much as possible." Professor Benett also says you should "wash your own hands more often in between touching things, even around the home" when you or someone else is sick. She recommends wiping down commonly used surfaces — such as the bathroom — more often. Any surfaces where someone has coughed may have droplets over them, she says. Professor Bennett says "bugs do so well [in winter because] we can't air our houses out". Poor ventilation will make it easier for viruses to spread, but she says increasing air turnover and introducing outdoor air can help. Open doors and windows when you can "so it's not the same air pushing right through the household that's around the person who's unwell." Dr Foo also says the more ventilation you can get at home the better, while of course avoiding hypothermia. Dr Foo says "the general advice all remains the same" if someone in the household is potentially more vulnerable. However, he says people more at risk of becoming seriously unwell may want to consult their regular healthcare professional who knows their medical history. "It really depends on that person's risk, their comorbidities and what ongoing conditions they have — and also to identify whether it's appropriate to use antiviral medication at that point in time." Professor Bennett says being diligent with mask wearing, hand washing and sanitising surfaces is particularly worth doing if someone in the house is vulnerable. Professor Bennett says being up to date with COVID-19 and influenza vaccinations will offer another layer of protection. "If you can't avoid infection in the household — and that's the hardest place to do it — then actually having some protection from severe illness is really important in influenza." In larger shared households there are more people to bring viruses home and that extra protection from vaccination is even more important, "particularly from severe illness in the vulnerable people in our households", Professor Bennett says. Dr Foo also encourages people to stay up to date with their vaccinations, "especially their annual flu vaccination and their COVID booster shots". This is general information only. For personal advice, you should see a qualified medical practitioner.
